Lucence Lights the Way at #ASCO22
Lucence presents promising new data of its NGS assay at the 58th Annual ASCO Meeting from June 3rd to 7th, 2022. Read More.
Redefining the Future of Early Cancer Detection
The earliest signals of cancer are subtle. To detect cancer earlier, we are dedicated to building sensitive blood-testing technologies that profile cancer both accurately and affordably.
At Lucence, we are shaping this future of precision cancer care by capturing both sequence and cell information, all in one blood draw.
Bringing Clarity to
Cancer Care Today
Physicians and patients urgently need information that drives their medical care. We currently deliver actionable insights through our proprietary technologies such as AmpliMark™. Real-world data has shown > 99% sensitivity of AmpliMark™ in detecting clinically relevant biomarkers for lung, breast, and blood cancers at 0.1% mutant allele frequency (MAF) limit of detection. Powered by AmpliMark™, our liquid biopsy test LiquidHALLMARK® is swift, simple and sensitive.
Learn more about LiquidHALLMARK®